CNSide® CSF Assay is Now Covered by UnitedHealthcare

CNSide Diagnostics logo

For patients with suspected Leptomeningeal Metastases, time matters – prompt diagnosis and treatment initiation are essential to improve the chances of controlling the disease, managing symptoms, and extending survival.

ACHIEVE CLARITY.

ACT WITH CERTAINTY.

Leptomeningeal Metastases (LM)

Get information about this devastating complication of advanced cancer.

Know the Signs

CNSide® Cerebrospinal Fluid Assay Platform

Expect more from CSF analysis to detect and monitor solid tumors.
Learn More

Our Company, Lab, and Dedicated Team

Learn about our core purpose today and aspirations for the future.
Connect Now

CNSide® (Pronounced: see-inside)

CNSide®, a proprietary, highly sensitive, cerebrospinal fluid (CSF) assay platform performed in a CLIA accredited laboratory, provides healthcare professionals with accurate, comprehensive data that enable detection, quantitative analysis, and molecular characterization of tumor cells.1 The resulting data are indispensable in diagnosing LM, identifying biomarkers, and monitoring the effects of treatment.2

What Physician Experts Say

Doctor Priya Kumthekar

“CNSide® is a more sensitive and definitive test for LM and has the potential to permit earlier diagnosis, manage our patients with more diagnostic precision, and hopefully improve therapeutic outcomes for our patients with LM.”

Priya Kumthekar, MD
Principal Investigator, FORESEE Clinical Trial
Professor of Neurology and Medicine, Northwestern University
Full bio

Health Insurance Coverage

The largest health insurance provider in the United States, UnitedHealthcare, covers the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration test for metastatic central nervous system cancer.
Read the full press release

Covered Lives

Expect more from your CSF tumor cell analysis.

Your cancer patients’ lives are counting on it.

Learn More
References: 1. Appel HR, Rubens M, Roy M, Kotecha R, et al. Comparative evaluation of the diagnostic and prognostic performance of CNSide® versus standard cytology for leptomeningeal disease. Neurooncol Adv. 2024;6(1):vdae071. 2. Sweed NT, Hsiao H-C, Blouw B, Pircher TJ, et al. A microfluidic, multi-antibody cell capture method to evaluate tumor cells in cerebrospinal fluid in patients with suspected leptomeningeal metastases. Arch Pathol Lab Med. 2025;149(3):242-252.